Impact of the metabolic syndrome on high-sensitivity C reactive protein levels in patients with acute coronary syndrome

Atherosclerosis

Volumn 207, Issue 2, 2009, Pages 591-596

  Kilic, Teoman ^a   Jneid, Hani ^b   Ural, Ertan ^a   Oner, Gokhan ^a   Sahin, Tayfun ^a   Kozdag, Guliz ^a   Kahraman, Goksel ^a   Ural, Dilek ^a  

^a KOCAELI UNIVERSITY   (Turkey)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Acute coronary syndrome; High sensitivity C reactive protein; Inflammatory response; Metabolic syndrome

Indexed keywords

C REACTIVE PROTEIN; TROPONIN;

ACUTE CORONARY SYNDROME; ADULT; ARTICLE; BODY MASS; CONTROLLED STUDY; DISEASE PREDISPOSITION; FEMALE; HIGH RISK PATIENT; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL;

ACUTE CORONARY SYNDROME; AGED; BIOLOGICAL MARKERS; BODY MASS INDEX; C-REACTIVE PROTEIN; CASE-CONTROL STUDIES; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; INFLAMMATION MEDIATORS; LOGISTIC MODELS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; ODDS RATIO; RISK ASSESSMENT; RISK FACTORS; TROPONIN; UP-REGULATION;

EID: 70450260676     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2009.05.035     Document Type: Article

References (43)

1. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med 340 (1999) 115-126
2. In: Ridker P.M., and Rifai N. (Eds). C reactive protein and cardiovascular disease (2006), MediEdition Inc., St-Laurent, Canada 393 ISBN: 0-9780090-0-2
3. Ridker P.M. Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation 107 (2003) 363-369
4. Libby P., and Simon D.I. Inflammation and thrombosis: the clot thickens. Circulation 103 (2001) 1718-1720
5. Ridker P.M., Buring J.E., Cook N.R., and Rifai N. C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14,719 initially healthy American women. Circulation 107 (2003) 391-397
6. Lindahl B., Toss H., Siegbahn A., Venge P., and Wallentin L. Markers of myocardial damage and inflammation in relation to long-term mortality in unstable coronary artery disease. FRISC Study Group. Fragmin during instability in coronary artery disease. N Engl J Med 343 (2000) 1139-1147
7. Morrow D.A., de Lemos J.A., Sabatine M.S., et al. Clinical relevance of C-reactive protein during follow-up of patients with acute coronary syndromes in the Aggrastat-to-Zocor Trial. Circulation 114 (2006) 281-288
8. De Servi S., Mariani M., Mariani G., and Mazzone A. C-reactive protein increase in unstable coronary disease cause or effect?. J Am Coll Cardiol 46 (2005) 1496-1502
9. Pepys M.B., and Hirshfield G.M. C-reactive protein: a critical update. J Clin Invest 111 (2003) 1805-1812
10. Frangogiannis N.G., Smith C.W., and Entman M.L. The inflammatory response in myocardial infarction. Cardiovasc Res 53 (2002) 31-47
11. Brunetti N.D., Pellegrino P.L., Correale M., Troccoli R., and Di Biase M. Early and late determinants of C-reactive protein release in patients with acute coronary syndrome. Int J Cardiol 112 (2006) 136-138
12. Liuzzo G., Buffon A., Biasucci L.M., et al. Enhanced inflammatory response to coronary angioplasty in patients with severe unstable angina. Circulation 98 (1998) 2370-2376
13. Celik T., Iyisoy A., Kursaklioglu H., Turhan H., and Isik E. Does the preexisting inflammation play a role in the increased C-reactive protein levels in acute myocardial infarction?. Int J Cardiol 112 (2006) 134-135
14. Grundy S.M. Inflammation, metabolic syndrome, and diet responsiveness. Circulation 108 (2003) 126-128
15. Frohlich M., Imhof A., Berg C., et al. Association between C-reactive protein and features of the metabolic syndrome: a population based study. Diabetes Care 23 (2000) 1835-1839
16. Alpert J.S., Thygesen K., Antman E., and Bassand J.P. Myocardial infarction redefined-a consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. J Am Coll Cardiol 36 (2000) 959-969
17. Antman E.M., Anbe D.T., Armstrong P.W., et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction-executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to revise the 1999 guidelines for the management of patients with acute myocardial infarction). J Am Coll Cardiol 44 (2004) 671-719
18. Executive summary of the third report of the National Cholesterol Education Program (NCEP). Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA 2001;285:2486-97.
19. Zeller M., Steg P.G., Ravisy J., et al. Prevalence and impact of metabolic syndrome on hospital outcomes in acute myocardial infarction. Arch Intern Med 165 (2005) 1192-1198
20. Norhammar A., Tenerz A., Nilsson G., et al. Glucose metabolism in patients with acute myocardial infarction and no previous diagnosis of diabetes mellitus: a prospective study. Lancet 359 (2002) 2140-2144
21. Ahnve S., Angelin B., Edhag O., and Berglund L. Early determination of serum lipids and apolipoproteins in acute myocardial infarction: possibility for immediate intervention. J Intern Med 226 (1989) 297-301
22. Henkin Y., Crystal E., Goldberg Y., et al. Usefulness of lipoprotein changes during acute coronary syndromes for predicting postdischarge lipoprotein levels. Am J Cardiol 89 (2002) 7-11
23. International Diabetes Federation: The IDF consensus worldwide definition of the metabolic syndrome [article online], available from http://www.idf.org/webdata/docs/metac_syndrome_def.pdf; 2005 [accessed on 19 October, 2005].
24. Grundy S.M., Cleeman J.I., Daniels S.R., et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 112 (2005) 2735-2752
25. Yip H.K., Wu C.J., Chang H.W., et al. Levels and values of serum high-sensitivity C-reactive protein within 6 hours after the onset of acute myocardial infarction. Chest 126 (2004) 1417-1422
26. Tomoda H., and Aoki N. Prognostic value of C-reactive protein levels within six hours after the onset of acute myocardial infarction. Am Heart J 140 (2000) 324-328
27. Pearson T.A., Mensah G.A., Alexander R.W., et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 107 (2003) 499-511
28. Myers GL, Rifai N, Tracy RP, et al. CDC/AHA Workshop on Markers of Inflammation and Cardiovascular Disease: application to clinical and public health practice: report from the laboratory science discussion group.
29. Das U.N. Metabolic syndrome X: an inflammatory condition?. Curr Hypertens Rep 6 (2004) 66-73
30. Fernandez-Real J.M., and Ricart W. Insulin resistance and chronic cardiovascular inflammatory syndrome. Endocr Rev 24 (2003) 278-301
31. Ben-Yehuda O. High-sensitivity C-reactive protein in every chart? The use of biomarkers in individual patients. J Am Coll Cardiol 49 (2007) 2139-2141
32. Feinberg M.S., Schwartz R., and Behar S. Impact of metabolic syndrome in patients with acute coronary syndrome. Adv Cardiol 45 (2008) 114-126
33. Clavijo L.C., Pinto T.L., Kuchulakanti P.K., et al. Metabolic syndrome in patients with acute myocardial infarction is associated with increased infarct size and in-hospital complications. Cardiovasc Revasc Med 7 (2006) 7-11
34. Schwartz G.G., Szarek M., Olsson A.G., and Sasiela W.J. Relation of characteristics of metabolic syndrome to short term prognosis and effects of statin therapy after acute coronary syndrome. Diabetes Care 28 (2005) 2013-2508
35. Levantesi, Macchia A., Marfisi R., et al. On behalf of the GISSI-Prevenzione Investigators: metabolic syndrome and risk of cardiovascular events after myocardial infarction. J Am Coll Cardiol 46 (2005) 277-283
36. Feinberg M.S., Schwartz R., Tanne D., et al. Impact of the metabolic syndrome on the clinical outcomes of nonclinically diagnosed diabetic patients with acute coronary syndrome. Am J Cardiol 99 (2007) 667-672
37. Nakatani D., Sakata Y., Hiroshi Sato H., et al. On behalf of the Osaka Acute Coronary Insufficiency Study (OACIS) Group: clinical impact of metabolic syndrome and its additive effect with smoking on subsequent cardiac events after acute myocardial infarction. Am J Cardiol 99 (2007) 885-889
38. Boulon C., Lafitte M., Richeboeuf V., et al. Prevalence of metabolic syndrome after acute coronary syndrome and its prognostic significance. Am J Cardiol 98 (2006) 1429-1434
39. Takeno M., Yasuda S., Otsuka Y., et al. Impact of metabolic syndrome on the long-term survival of patients with acute myocardial infarction: potential association with C-reactive protein. Circ J 72 (2008) 415-419
40. Gami A.S., Witt B.J., Howard D.E., et al. Metabolic syndrome and risk of incident cardiovascular events and death: a systematic review and meta-analysis of longitudinal studies. J Am Coll Cardiol 49 (2007) 403-414
41. Inchiostro S., Fadini G.P., de Kreutzenberg S.V., Citroni N., and Avogaro A. Is the metabolic syndrome a cardiovascular risk factor beyond its specific components?. J Am Coll Cardiol 49 (2007) 2465 [author reply 2465-6]
42. Lin M.S., Shih S.R., Li H.Y., et al. Serum C-reactive protein levels correlates better to metabolic syndrome defined by International Diabetes Federation than by NCEP ATP III in men. Diabetes Res Clin Pract 77 (2007) 286-292
43. Hirsso P.K., Timonen M.J., Jokelainen J.J., et al. Association between high-sensitive measurement of C-reactive protein and metabolic syndrome as defined by International Diabetes Federation, National Cholesterol Education Program, and World Health Organization criteria in a population-based cohort of 55-year-old Finnish individuals. Diabetes Care 29 (2006) 2177-2178